A closer reading

Body copy for /team/

Who writes this site

Dr. Alexander Tabibi, MD, is the author of record for everything published on Citicoline.co. He trained in internal medicine at USC Keck, and he writes, reviews, and signs the content on every page of this reference.

That last point matters more than it might seem. Many health websites present a long list of medical reviewers, editors, and contributors. Some of those lists are real. Many are decorative, names added to make a page look supervised when no physician actually read it. This site takes the opposite approach. There is one author of record, and this site does not invent a larger staff. When you read a page here, you know exactly who stands behind it.

Internal medicine is a relevant background for this subject. Citicoline (CDP-choline) sits at the intersection of neurology-adjacent claims and everyday supplement use. The people asking about it are often adults managing blood pressure, cholesterol, diabetes, or recovery from illness, the daily work of an internist. The questions are practical: Is the evidence real? Does it apply to me? Is it safe with what I already take? Those are the questions this site is built to answer plainly.

Why this site exists

Citicoline is one of the most over-claimed supplements sold in the United States. Marketing language routinely describes it as proven to restore memory, protect the brain after stroke, sharpen attention, and slow cognitive decline. The actual evidence is much more mixed than that language suggests, and in several important areas the best and largest trials were negative.

Consider stroke. Earlier meta-analyses of smaller trials suggested citicoline might improve recovery after an acute stroke. Then the ICTUS trial, roughly 2,300 people, published in The Lancet in 2012, found no improvement in 90-day recovery compared with placebo. The largest and most careful test of the claim did not confirm the earlier optimism. A site that cites only the older meta-analyses would leave you with a false picture.

The same pattern appears in traumatic brain injury. The COBRIT trial, published in JAMA in 2012, found that citicoline did not improve functional or cognitive outcomes versus placebo. That is a high-quality negative result, and it deserves the same visibility as any positive finding.

Meanwhile, some claims have genuinely interesting, if limited, support. Small trials have found better attention-test scores in healthy women and adolescent males at studied doses, though those studies were funded by the maker of a branded citicoline ingredient. A Cochrane review of chronic cerebrovascular cognitive decline found modest short-term benefit on memory and behaviour, while noting the trials were short and low in quality. None of this amounts to proof, but it is not nothing either.

This site exists to hold both halves of that story at once: the positive findings, stated with their limits, and the negative trials, stated without softening. You can read the full breakdown on the citicoline evidence, condition by condition page.

How claims are graded here

Every substantive claim on this site is tied to a tier of evidence, and the language is calibrated to match. The system, in plain terms:

  • Largest randomized trials carry the most weight. When a big, well-run trial disagrees with smaller earlier studies, the big trial wins. That is why the stroke and brain injury pages lead with ICTUS and COBRIT rather than with older, more hopeful summaries.
  • Meta-analyses and systematic reviews come next. They are useful but only as good as the trials they pool. The Cochrane finding on cerebrovascular cognitive decline is reported alongside its own caveat: the underlying trials were short and low quality.
  • Observational studies can show association but not cause. The IDEALE study, for example, linked citicoline use with stable cognitive scores compared with decline in an untreated group. That is hypothesis-generating, not proof, and the site says so.
  • Mechanistic and preclinical evidence is labeled as such. Evidence suggests citicoline supports membrane phospholipid synthesis, and neuroprotective effects have been seen in preclinical work. Preclinical means animal or laboratory data. It does not mean the effect has been shown in people.
  • Absence of evidence is stated plainly. For ADHD, there are no adequate trials. There is no good evidence citicoline treats ADHD, and the citicoline and ADHD page says exactly that rather than hinting otherwise.

Where a study was industry funded, that fact is disclosed next to the finding, because funding source is part of how a careful reader weighs a result.

What this site will not say

Some sentences will never appear here, no matter how common they are elsewhere:

  • That citicoline treats, cures, reverses, or prevents stroke, dementia, glaucoma, ADHD, or brain injury. It does not, and the evidence does not support those verbs.
  • That a negative trial "needs more research" in a way that quietly buries it. The ICTUS and COBRIT results are answers, not placeholders.
  • That a mechanism implies a benefit. A plausible pathway in a lab dish is not a clinical outcome.
  • That a specific product, brand, or dose is right for you. Doses studied in trials, generally 250 to 2,000 mg per day, are described on the citicoline doses used in studies page for context, not as personal recommendations.
  • That a small positive trial settles a question. The glaucoma research, for instance, showed changes in electrophysiological measures, but whether citicoline affects actual vision loss is not established.

Safety and medical boundaries

Citicoline is generally well tolerated in trials, with mild side effects such as stomach upset, headache, and insomnia reported. But "generally well tolerated" is not the same as "right for everyone." Pregnancy and breastfeeding data are lacking. Citicoline may enhance the effects of levodopa, so anyone with Parkinson's disease should involve their neurologist before taking it. The citicoline safety and citicoline side effects pages cover this in detail.

Two boundaries are absolute. First, nothing on this site replaces a conversation with your own clinician, who knows your history and medications. The questions to ask your doctor page exists for exactly that conversation. Second, some symptoms are emergencies regardless of anything you read here: sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately.

One compound, several names

Part of the confusion around this supplement is naming. Citicoline and CDP-choline are the same compound. Cognizin is a brand of that compound, not a different molecule, and studies funded by the brand are studies of citicoline, labeled as industry funded on this site. In the United States, citicoline is sold as a dietary supplement, not an FDA-approved drug. The CDP-choline and citicoline and what Cognizin is pages untangle the terminology.

Corrections and contact

A single-author reference has a single point of accountability. If you find an error, an outdated citation, or a claim that reads stronger than the evidence supports, that is a fixable problem and one the author wants to hear about. Reach the site through the contact Citicoline.co page. For the broader picture of how the site is run, see about Citicoline.co, or start from the citicoline evidence, without the hype homepage.